Skip to content

Year-end report 2021: STRONG END TO A TRANSFORMATIVE YEAR

FOURTH QUARTER 2021 (OCT – DEC)

Net sales amounted to SEK 197.7 million (39.6), corresponding to an increase of 399 percent compared with the corresponding period in the preceding year. Fourth quarter sales included an item of SEK 9.5 million attributable to the adjustment of accounting principles regarding the period in which certain income is reported.

Simbionix and Mimic are included in the amount of SEK 138.7 million combined. For comparable units, sales increased by 31 percent.

Operating profit amounted to SEK 44.5 million (12.6).

Net profit amounted to SEK 66.9 million (10.6), corresponding to earnings per share of SEK 1.32 (0.31).

Cash flow from operating activities amounted to a net outflow of SEK 13.0 million (inflow 16.7). As of December 31, 2021, cash and cash equivalents amounted to SEK 316.7 million (87.2).

FULL-YEAR 2021

Net sales amounted to SEK 366.8 million (104.8), corresponding to an increase of 250 percent compared with the preceding year.

For comparable units, sales increased by 34 percent.

Pro forma, the Group’s sales for 2021 amounted to SEK 597.0 million (500.9), an increase of 19 percent.

Operating profit amounted to SEK 56.5 million (20.0). The outcome includes acquisition costs of SEK 28.5 million.

Net profit amounted to SEK 86.2 million (15.6), corresponding to earnings per share of SEK 2.03 (0.45).

Cash flow from operating activities amounted to SEK 39.1 million (23.2).

In January, Mimic Technologies was acquired, with operations in robotic surgery. The transfer of ownership took place on January 27.

In August, Simbionix was acquired, further strengthening Surgical Science’s position in simulation for robotic surgery and broadening the operations with new application areas. The transfer of ownership took place on August 24.

Gothenburg, Sweden, February 16, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Skip to navigation